Table 3.
Unadjusted and adjusted time-dependent (cancer diagnosis to COVID-19 diagnosis) Cox-regression analysis and all-cause mortality—Indiana, 2019-2020.
| Variable | Unadjusted | Adjusted | |||||||
|
|
Estimate (SE) | Hazard ratio (95% CI) | P value | Estimate (SE) | Hazard ratio (95% CI) | P value | |||
| Covid-19 diagnosis |
|
||||||||
|
|
No | N/Aa | Reference | <.001 | N/A | Reference | <.001 | ||
|
|
Yes | 1.87 (0.07) | 6.53 (5.72-7.44) |
|
1.93 (0.07) | 6.91 (6.06-7.89) |
|
||
| Age group (years) |
|
||||||||
|
|
8-44 | N/A | Reference | <.001 | N/A | Reference |
|
||
|
|
45-64 | 0.69 (0.09) | 2.00 (1.65-2.42) |
|
0.65 (0.09) | 1.91 (1.57-2.32) |
|
||
|
|
≥65 | 1.20 (0.09) | 3.10 (2.54-3.70) |
|
1.01 (0.09) | 2.74 (2.26-3.31) |
|
||
| Sex |
|
||||||||
|
|
Female | N/A | Reference | <.001 | N/A | Reference | <.001 | ||
|
|
Male | 0.19 (0.03) | 1.21 (1.13-1.30) |
|
0.21 (0.04) | 1.23 (1.14-1.32) |
|
||
| Race or ethnicity |
|
||||||||
|
|
White | N/A | Reference | <.001 | N/A | Reference | <.001 | ||
|
|
Black | 0.11 (0.06) | 1.12 (0.98-1.27) |
|
0.10 (0.06) | 1.11 (0.97-1.26) |
|
||
|
|
Hispanic | –0.50 (0.15) | 0.60 (0.45-0.81) |
|
–0.47 (0.15) | 0.62 (0.46-0.84) |
|
||
|
|
Other | –0.34 (0.06) | 0.71 (0.63-0.80) |
|
–0.23 (0.06) | 0.79 (0.70-0.90) |
|
||
| Comorbidities |
|
||||||||
|
|
0 | N/A | Reference | <.001 | N/A | Reference | <.001 | ||
|
|
1 | 0.65 (0.04) | 1.91 (1.75-2.07) |
|
0.37 (0.04) | 1.44 (1.33-1.57) |
|
||
|
|
≥2 | 1.15 (0.04) | 3.16 (2.90-3.43) |
|
0.75 (0.04) | 2.12 (1.94-2.31) |
|
||
| Cancer |
|
||||||||
|
|
Other | N/A | Reference | <.001 | N/A | Reference | <.001 | ||
|
|
Breast | –1.51 (0.09) | 0.22 (0.18-0.26) |
|
–1.43 (0.09) | 0.24 (0.20-0.29) |
|
||
|
|
Colorectal | –0.41 (0.07) | 0.67 (0.57-0.78) |
|
–0.51 (0.07) | 0.60 (0.51-0.70) |
|
||
|
|
Leukemia | 0.03 (0.08) | 1.03 (0.87-1.22) |
|
–0.10 (0.09) | 0.90 (0.76-1.07) |
|
||
|
|
Lip, oral cavity, and pharynx | –0.31 (0.12) | 0.73 (0.58-0.93) |
|
–0.39 (0.12) | 0.67 (0.53-0.86) |
|
||
|
|
Lung and bronchus | 0.63 (0.05) | 1.87 (1.69-2.07) |
|
0.38 (0.05) | 1.45 (1.31-1.61) |
|
||
|
|
Lymphoma | –0.25 (0.09) | 0.79 (0.66-0.94) |
|
–0.31 (0.09) | 0.73 (0.61-0.87) |
|
||
|
|
Myeloma | –0.24 (0.12) | 0.78 (0.61-0.99) |
|
–0.44 (0.12) | 0.64 (0.50-0.82) |
|
||
|
|
Other digestive | 0.78 (0.05) | 2.18 (1.96-2.43) |
|
0.58 (0.05) | 1.80 (1.61-2.00) |
|
||
|
|
Other hematological | –0.90 (0.33) | 0.41 (0.21-0.78) |
|
–1.06 (0.33) | 0.35 (0.18-0.67) |
|
||
|
|
Prostate | –1.38 (0.09) | 0.25 (0.21-0.30) |
|
–1.64 (0.09) | 0.19 (0.16-0.23) |
|
||
|
|
Melanoma | –1.43 (0.09) | 0.24 (0.20-0.28) |
|
–1.56 (0.09) | 0.21 (0.17-0.25) |
|
||
|
|
Urinary tract | –0.39 (0.08) | 0.67 (0.58-0.79) |
|
–0.68 (0.08) | 0.50 (0.43-0.59) |
|
||
| Region |
|
||||||||
|
|
Urban | N/A | Reference | <.001 | N/A | Reference | <.001 | ||
|
|
Rural | 0.13 (0.04) | 1.14 (1.06-1.23) |
|
0.08 (0.04) | 1.09 (1.01-1.18) |
|
||
aN/A: not applicable.